Aspirin vs Naproxen
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Aspirin and naproxen are both nonsteroidal anti-inflammatory drugs (NSAIDs) with analgesic, anti-inflammatory, and antipyretic properties, but they serve different clinical roles [1][2]. While both inhibit cyclooxygenase enzymes, aspirin uniquely and irreversibly inhibits COX-1, providing antiplatelet effects that make it a cornerstone of cardiovascular prevention.
Low-dose aspirin (75-325 mg) is widely used for secondary prevention of heart attack and stroke — an indication no other OTC NSAID shares [1][3]. Naproxen is primarily used for pain and inflammation from arthritis, injuries, and other musculoskeletal conditions [2].
Among NSAIDs, naproxen has shown the most favorable cardiovascular safety profile in comparative studies, making it a common choice for patients who need anti-inflammatory therapy alongside cardiovascular risk management [2][4].
Aspirin vs Naproxen: Side-by-side comparison
| Category | Aspirin | Naproxen |
|---|---|---|
| Drug Class | NSAID (irreversible COX inhibitor) | NSAID (reversible COX inhibitor) |
| Generic Name | Aspirin (acetylsalicylic acid) | Naproxen sodium |
| Brand Name | Bayer, Ecotrin | Aleve |
| FDA Approved For | Pain, fever, inflammation, cardiovascular prevention | Pain, fever, inflammation, arthritis |
| How It Works | Irreversibly inhibits COX-1 and COX-2 | Reversibly inhibits COX-1 and COX-2 |
| Antiplatelet Effect | Yes (irreversible, lasts platelet lifetime) | Minimal (reversible) |
| Typical Dose | 81-325 mg/day (CV); 325-1000 mg q4-6h (pain) | 220-440 mg every 8-12 hours (OTC) |
| Common Side Effects | GI bleeding, dyspepsia, bruising | Dyspepsia, nausea, abdominal pain, edema |
| Unique Risk | Reye syndrome in children | Standard NSAID GI/CV/renal risks |
| CV Prevention Role | Yes — secondary prevention standard of care | No — but most CV-favorable NSAID |
| Cost (OTC) | $2-$6/month | $4-$10/month |
| Safe for Children | Not for viral illness (Reye syndrome risk) | Generally avoided under age 12 |
Efficacy: How well does each drug work?
For pain and inflammation, naproxen at analgesic doses (250-500 mg twice daily) is substantially more effective than low-dose aspirin [2]. At anti-inflammatory doses (3.6-5.4 g/day), aspirin is effective but rarely used due to toxicity concerns. Naproxen is the preferred NSAID for conditions like osteoarthritis, rheumatoid arthritis, and acute musculoskeletal pain [2].
For cardiovascular prevention, low-dose aspirin is the established standard of care for secondary prevention in patients with known cardiovascular disease [1][3]. The antiplatelet effect of aspirin (irreversible COX-1 inhibition in platelets) is unique — naproxen and other NSAIDs have reversible antiplatelet effects that do not provide the same level of cardiovascular protection [1][3].
The PRECISION trial found naproxen to be non-inferior to celecoxib and ibuprofen for cardiovascular safety, supporting its use when long-term NSAID therapy is needed in patients with cardiovascular risk factors [4].
Side effects comparison
Both medications share NSAID class risks for GI bleeding and renal impairment [1][2]. Aspirin at any dose can cause GI bleeding; the risk increases with dose and duration. Low-dose aspirin causes less GI toxicity than analgesic doses but still increases bleeding risk by 2-3 fold compared to no aspirin [1][3].
Naproxen at standard doses causes GI side effects in approximately 14% of patients (dyspepsia, nausea, abdominal pain) [2]. Combining aspirin and naproxen substantially increases GI bleeding risk.
An important drug interaction: naproxen can interfere with aspirin's antiplatelet effect if taken concurrently. The FDA advises taking aspirin at least 30 minutes before or 8 hours after naproxen to preserve aspirin's cardioprotective effects [1].
Aspirin uniquely causes Reye syndrome risk in children with viral illness — it should not be given to children or teenagers with flu or chickenpox symptoms [1]. Naproxen does not carry this risk but is generally avoided under age 12 [2].
Cost comparison
Convenience and dosing
Low-dose aspirin for cardiovascular prevention is taken once daily (81-325 mg) [1]. Naproxen for pain is taken every 8-12 hours (220 mg OTC or 250-500 mg Rx) [2]. Both are available OTC. Aspirin's once-daily cardiovascular dosing is simpler than naproxen's pain dosing. Enteric-coated aspirin formulations may reduce (but not eliminate) GI effects.
Which is right for you?
Aspirin at low doses is the right choice for cardiovascular prevention in patients with established heart disease or stroke history — this is not a role naproxen can fill [1][3]. Naproxen is the better choice for pain and inflammation management, especially in patients with cardiovascular risk factors where an NSAID is needed [2][4].
If you take daily aspirin for heart protection and need an NSAID for pain, naproxen or another NSAID can be used, but timing must be managed to avoid interference with aspirin's antiplatelet effect [1]. Consult your healthcare provider for guidance.
This information is for educational purposes only.
Frequently asked questions
References
- [Regulatory] Aspirin prescribing information. FDA-approved labeling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019884s042lbl.pdf Accessed 2025-06-15.
- [Regulatory] Naproxen sodium prescribing information. FDA-approved labeling. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020204s048lbl.pdf Accessed 2025-06-15.
- [Regulatory] Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease. Lancet. 2009;373(9678):1849-1860. https://doi.org/10.1016/S0140-6736(09)60503-1 Accessed 2025-06-15.
- [Regulatory] Nissen SE, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis (PRECISION). N Engl J Med. 2016;375(26):2519-2529. https://doi.org/10.1056/NEJMoa1611593 Accessed 2025-06-15.
- [Observational] GoodRx price comparison: aspirin and naproxen. https://www.goodrx.com Accessed 2025-06-15.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: